Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.540 -0.020 (-0.30%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 13, 2023

Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.

Via Benzinga

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 21, 2023

Via Benzinga

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 21, 2023

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 02, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

February 28, 2023

During Tuesday, 79 stocks hit new 52-week lows.

Via Benzinga

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU

February 16, 2023

From ImmunityBio, Inc.

Via Business Wire

Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 15, 2023

Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.

Via Benzinga

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

February 15, 2023

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

January 19, 2023

From ImmunityBio, Inc.

Via Business Wire

Tesla, Hyzon Motors And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 29, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

December 12, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference

November 17, 2022

From ImmunityBio, Inc.

Via Business Wire

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer

November 10, 2022

From ImmunityBio

Via Business Wire

ImmunityBio to Participate in the Jefferies London Healthcare Conference

October 27, 2022

From ImmunityBio, Inc.

Via Business Wire

Worthington Industries, CarMax And Other Big Losers From Thursday ↗

September 30, 2022

U.S. stocks closed lower with the Nasdaq Composite dropping more than 300 points on Thursday. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Nikola, Super Micro Computer And Other Big Losers From Monday ↗

September 20, 2022

U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Twilio, AMTD Digital And Other Big Gainers From Wednesday ↗

September 15, 2022

U.S. stocks closed mostly higher with the Nasdaq 100 gaining around 100 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗

September 20, 2022

Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗

September 19, 2022

Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.

Via Benzinga

Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket ↗

August 29, 2022

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q.

Via Benzinga

Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗

September 15, 2022

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗

August 03, 2022

Via Benzinga

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday ↗

September 15, 2022

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗

July 28, 2022

Via Benzinga

FDA Accepts ImmunityBio's Bladder Cancer Candidate For Review ↗

July 28, 2022

The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s (NASDAQ: IBRX) Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

All News about ImmunityBio, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today